KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Accumulated Depreciation & Amortization (2017 - 2026)

Aquestive Therapeutics has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $44.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 1.2% year-over-year to $44.0 million; the TTM value through Dec 2025 reached $44.0 million, up 1.2%, while the annual FY2025 figure was $44.0 million, 1.2% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $44.0 million at Aquestive Therapeutics, roughly flat from $43.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $44.0 million in Q4 2025 and troughed at $37.8 million in Q1 2021.
  • A 5-year average of $42.0 million and a median of $42.6 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: dropped 2.49% in 2021 and later increased 7.11% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $39.9 million in 2021, then rose by 5.28% to $42.0 million in 2022, then increased by 2.19% to $42.9 million in 2023, then grew by 1.44% to $43.5 million in 2024, then rose by 1.2% to $44.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for AQST at $44.0 million in Q4 2025, $43.9 million in Q3 2025, and $43.8 million in Q2 2025.